No reinduction of clinically relevant radioiodine uptake after lenvatinib treatment in radioidine-refractory differentiated thyroid cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2026-05 · 53 (6) · 3664-3673
DOI: 10.1007/s00259-025-07662-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 16.12.2025. Verfasst von Maaike Dotinga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Quinolines, Iodine Radioisotopes, Thyroid Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Prior studies show that short-term treatment using tyrosine kinase inhibitors (TKIs) can reinduce radioiodine uptake and warrant 131I therapy in radioiodine-refractory differentiated thyroid cancer (RAI-R DTC). We aim to evaluate the potential of standard-of-care TKI lenvatinib to reinduce clinically meaningful radioiodine retention. METHODS: Nine RAI-R DTC patients starting lenvatinib treatment for progressive advanced or metastatic disease, were included and underwent rhTSH-stimulated 124I dosimetric procedures at baseline, week 6 (N=7) and week 12 (N=8). At all timepoints, the fraction of patients eligible for 131I therapy with a maximal activity of 7.4 GBq was assessed. Patients were considered eligible if at least one target lesion showed an expected mean absorbed dose ≥20 Gy. In total, 23 target lesions were segmented on124I PET/CT images and their volumes estimated using low-dose CT images. Lesion size-specific recovery correction was applied to the measured mean activity concentration at each timepoint. Tumor dosimetry was performed using a mono-exponential fit and S-values from an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms (IDAC-Dose2.1). Mean absorbed lesion dose per administered activity (LDpA), 24h-uptake and residence time in target lesions were compared between time points. RESULTS: By our definition, none of the patients were found eligible for 131I therapy at any timepoint. Lenvatinib-induced partial response was observed in 59% and 75% of target lesions at week 6 and 12, respectively. Median LDpA was 0.08 (IQR: 0.04-0.17), 0.18 (0.08-0.36) and 0.17 (0.09-0.37) Gy/GBq for week 0, 6 and 12, respectively (p=0.08). The 24h-uptake and residence time were comparable between timepoints (p>0.22). CONCLUSION: Redifferentiation of RAI-R DTC to reinduce radioiodine uptake to a level that warrants 131I therapy may not be established by short-term lenvatinib treatment. Multi-targeted TKIs may not be as potent as selective TKIs in reinducing clinically meaningful radioiodine retention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Biomedical Photonic Imaging, University of Twente, Enschede, The Netherlands.
- Department of Radiation Science and Technology, Delft University of Technology, Delft, The Netherlands.
- Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Nuclear Medicine, Alrijne hospital, Leiderdorp, The Netherlands.
ORCID-Profile: Maaike Dotinga, Lioe-Fee de Geus-Oei, Floris H P van Velden, Mette K Stam, Jan W T Heemskerk, Petra Dibbets-Schneider, Martin Pool, Dennis Vriens, Ellen Kapiteijn
Zitieren
APA
Dotinga, M., de Geus-Oei, L. F., van Velden, F. H. P., Stam, M. K., Heemskerk, J. W. T., Dibbets-Schneider, P., Pool, M., Smit, F., Vriens, D., & Kapiteijn, E. (2026). No reinduction of clinically relevant radioiodine uptake after lenvatinib treatment in radioidine-refractory differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53(6), 3664-3673. https://doi.org/10.1007/s00259-025-07662-9
Vancouver
Dotinga M, de Geus-Oei LF, van Velden FHP, Stam MK, Heemskerk JWT, Dibbets-Schneider P, et al. No reinduction of clinically relevant radioiodine uptake after lenvatinib treatment in radioidine-refractory differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(6):3664-3673. doi:10.1007/s00259-025-07662-9
BibTeX
@article{Dotinga2026,
author = {Dotinga, Maaike and de Geus-Oei, Lioe-Fee and van Velden, Floris H P and Stam, Mette K and Heemskerk, Jan W T and Dibbets-Schneider, Petra and Pool, Martin and Smit, Frits and Vriens, Dennis and Kapiteijn, Ellen},
title = {No reinduction of clinically relevant radioiodine uptake after lenvatinib treatment in radioidine-refractory differentiated thyroid cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {6},
pages = {3664--3673},
doi = {10.1007/s00259-025-07662-9}
}
EUVIMED